Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-617 for prevention and reduction of chemoradiation-induced oral mucositis in head and neck cancer
ACTRN12620000540910Phase 2Not yet recruiting
- Sponsor
- PSI CRO
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in stomatitis comparing ST-617 treatment arm with Placebo control arm (2 arms). Primary endpoint: Duration of severe oral mucositis. Planned start May 2021; status: not yet recruiting.
02
Drugs
ST-617
03
Conditions
stomatitis
Beyond the preview
Go deeper on ACTRN12620000540910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000540910.